GlaxoSmithKline, AstraZeneca butt heads over licensing rights to key PARP inhibitor — report

Max Gelman

Senior Editor

Ahead of GlaxoSmithKline’s planned split into two companies and spin-off of its consumer divisions, the pharma’s major British rival is reportedly suing over a drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

GlaxoSmithKline, AstraZeneca butt heads over licensing rights to key PARP inhibitor — report

Max Gelman

Senior Editor

Sign up to read this article for free.

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

Glax­o­SmithK­line, As­traZeneca butt heads over li­cens­ing rights to key PARP in­hibitor — re­port

Max Gelman

Senior Editor

Sign up to read this article for free.

more like this

Trump team asked Warp Speed leader to head NIH, may seek more tra­di­tion­al pick for role

Bris­tol My­ers re­veals more job cuts in New Jer­sey

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

In­cyte touts Mon­ju­vi da­ta from Phase 3 fol­lic­u­lar lym­phoma tri­al as it heads to FDA

Trump taps Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, sur­geon gen­er­al picks

Cas­sa­va shares plunge as con­tro­ver­sial Alzheimer’s drug fails Phase 3 tri­al

GlaxoSmithKline, AstraZeneca butt heads over licensing rights to key PARP inhibitor — report

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

Bristol Myers reveals more job cuts in New Jersey

How did Trump’s FDA pick land? Biotech stocks are up, and executives are (mostly) relieved

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial